Abstract
Introduction: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI). Objective: In this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy
... read more